# DarioHealth Corp.: overview DRIO · Nasdaq · CIK 1533998 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/drio.md) · [Financials](/companies/drio/financials.md) · [Filings](/companies/drio/filings.md) · [Insiders](/companies/drio/insiders.md) Latest reported revenue: [$5.2m](/filings/0001104659-26-093645.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001104659-26-093645). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [7,423](/filings/0001104659-25-110730.md) | [7,604 d](/filings/0001104659-26-031621.md) | [6,752](/filings/0001104659-26-059676.md) | [5,369](/filings/0001104659-26-093645.md) | [5,007](/filings/0001104659-25-110730.md) | [5,231 d](/filings/0001104659-26-031621.md) | [5,584](/filings/0001104659-26-059676.md) | [5,177](/filings/0001104659-26-093645.md) | | Gross margin | % | [52.2%](/filings/0001104659-25-110730.md) | [55.3% d](/filings/0001104659-26-031621.md) | [57.5%](/filings/0001104659-26-059676.md) | [55.2%](/filings/0001104659-26-093645.md) | [60.2%](/filings/0001104659-25-110730.md) | [53.6% d](/filings/0001104659-26-031621.md) | [57.3%](/filings/0001104659-26-059676.md) | [61.7%](/filings/0001104659-26-093645.md) | | Operating margin | % | [(162.1%)](/filings/0001104659-25-110730.md) | [(153.4%) d](/filings/0001104659-26-031621.md) | [(139.4%)](/filings/0001104659-26-059676.md) | [(171.4%)](/filings/0001104659-26-093645.md) | [(189.4%)](/filings/0001104659-25-110730.md) | [(163.7%) d](/filings/0001104659-26-031621.md) | [(130.9%)](/filings/0001104659-26-059676.md) | [(125.1%)](/filings/0001104659-26-093645.md) | | Net margin | % | [(166.1%)](/filings/0001104659-25-110730.md) | [(126.7%) d](/filings/0001104659-26-031621.md) | [(136.7%)](/filings/0001104659-26-059676.md) | [(241.9%)](/filings/0001104659-26-093645.md) | [(209.0%)](/filings/0001104659-25-110730.md) | [(172.6%) d](/filings/0001104659-26-031621.md) | [(147.7%)](/filings/0001104659-26-059676.md) | [(153.1%)](/filings/0001104659-26-093645.md) | | Diluted EPS | $ per share | [4.91](/filings/0001104659-25-110730.md) | not reported | [2.87](/filings/0001104659-26-059676.md) | [3.54](/filings/0001104659-26-093645.md) | [2.96](/filings/0001104659-25-110730.md) | not reported | [1.25](/filings/0001104659-26-059676.md) | [0.85](/filings/0001104659-26-093645.md) | | Free cash flow | $k | [(7,389) d](/filings/0001104659-25-110730.md) | [(6,753) d](/filings/0001104659-26-031621.md) | [(6,704)](/filings/0001104659-26-059676.md) | [(6,075) d](/filings/0001104659-26-093645.md) | [(7,391) d](/filings/0001104659-25-110730.md) | [(5,913) d](/filings/0001104659-26-031621.md) | [(6,056)](/filings/0001104659-26-059676.md) | [(6,121) d](/filings/0001104659-26-093645.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [20.5](/filings/0001558370-23-003240.md) | [27.7](/filings/0001558370-24-004151.md) | [20.4](/filings/0001558370-25-002527.md) | [27.0](/filings/0001104659-26-031621.md) | [22.4](/filings/0001104659-26-031621.md) | | Gross margin | % | [19.3%](/filings/0001558370-23-003240.md) | [34.9%](/filings/0001558370-24-004151.md) | [29.4%](/filings/0001558370-25-002527.md) | [49.1%](/filings/0001104659-26-031621.md) | [56.6%](/filings/0001104659-26-031621.md) | | Operating margin | % | [(372.9%)](/filings/0001558370-23-003240.md) | [(205.4%)](/filings/0001558370-24-004151.md) | [(276.1%)](/filings/0001558370-25-002527.md) | [(213.6%)](/filings/0001104659-26-031621.md) | [(163.9%)](/filings/0001104659-26-031621.md) | | Net margin | % | [(374.2%)](/filings/0001558370-23-003240.md) | [(224.9%)](/filings/0001558370-24-004151.md) | [(292.0%)](/filings/0001558370-25-002527.md) | [(158.1%)](/filings/0001104659-26-031621.md) | [(186.6%)](/filings/0001104659-26-031621.md) | | Diluted EPS | $ per share | [4.07](/filings/0001558370-23-003240.md) | [2.54](/filings/0001558370-24-004151.md) | [1.93](/filings/0001558370-25-002527.md) | [12.27](/filings/0001104659-26-031621.md) | [10.12](/filings/0001104659-26-031621.md) | | Free cash flow | $m | [(50.7)](/filings/0001558370-23-003240.md) | [(48.3)](/filings/0001558370-24-004151.md) | [(31.0)](/filings/0001558370-25-002527.md) | [(38.7)](/filings/0001104659-26-031621.md) | [(26.1)](/filings/0001104659-26-031621.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/drio/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $4.0m | 610,691 | | Added +1 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $4.0m | 610,691 | | Added +1 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $433.5k | 65,675 | | Reduced −235 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $383.3k | 58,035 | | Reduced −3,843 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $249.5k | 37,796 | | Added +18,978 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $246.8k | 37,387 | | Added +7,317 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $160.3k | 24,289 | | Added +3,829 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $87.4k | 13,237 | | Unchanged | | [Vanguard Global Advisers, LLC](/funds/1811242.md) | 2026-06-30 | $21.9k | 3,321 | | Unchanged | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $19.8k | 3,000 | | Added +2,000 | ## Recent filings [All 903 filings](/companies/drio/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-04 | 16:05 ET | [8-K](/filings/0001104659-26-105495.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-105495 | | 2026-08-21 | 16:05 ET | [8-K](/filings/0001104659-26-099678.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-099678 | | 2026-08-11 | 06:05 ET | [10-Q](/filings/0001104659-26-093645.md) | Quarterly report, period 2026-06-30 | 0001104659-26-093645 | | 2026-07-22 | 17:19 ET | [8-K](/filings/0001104659-26-085900.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-085900 | | 2026-07-10 | 17:10 ET | [8-K](/filings/0001104659-26-082715.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-082715 | | 2026-05-13 | 06:05 ET | [10-Q](/filings/0001104659-26-059676.md) | Quarterly report, period 2026-03-31 | 0001104659-26-059676 | | 2026-04-13 | 08:21 ET | [8-K](/filings/0001104659-26-042362.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-042362 | | 2026-03-30 | 17:31 ET | [8-K](/filings/0001104659-26-036834.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-26-036834 | | 2026-03-19 | 06:05 ET | [10-K](/filings/0001104659-26-031621.md) | Annual report, period 2025-12-31 | 0001104659-26-031621 | | 2026-02-02 | 16:32 ET | [8-K](/filings/0001104659-26-009247.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001104659-26-009247 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-031621.md), filed Mar 19, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/8bd22984-ea5f-4125-9dd4-4ce67d6b48f1) ## About the filer - CIK: 1533998 - Tickers: DRIO - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.